Related Experiment Video
Updated: Jan 8, 2026
Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
Published on: July 26, 2017
Design, Synthesis, and Structure-Activity Relationship of Novel Human TLR1/2 Agonists for Potential Immunotherapy
Qiuyue Fu1, Yue Pan1, Peixi Wu1
1Guangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism and Guangdong-Hong Kong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Researchers developed SMU-C409, a potent and low-toxicity Toll-like receptor 2 (TLR2) agonist for cancer therapy. This novel compound enhances stability and solubility, showing promise for effective cancer immunotherapy.
Area of Science:
- Immunology
- Medicinal Chemistry
- Pharmacology
Background:
- Toll-like receptor 2 (TLR2) agonists offer potential in cancer therapy due to high potency and low toxicity.
- Existing TLR2 agonists face limitations such as degradation and poor solubility, hindering their clinical application.
Purpose of the Study:
- To design and synthesize novel thiourea-based TLR2 agonists with improved pharmacokinetic properties.
- To identify a low-toxicity, potent, and stable TLR1/2-specific small molecule agonist for cancer immunotherapy.
Main Methods:
- Design and synthesis of a novel series of thiourea-based TLR2 agonists.
- Characterization of SMU-C409 for potency (EC50), stability, solubility, and mechanism of action.
- In vitro evaluation of immune cell activation and antitumor immunomodulation.
Main Results:
- Identified SMU-C409, a TLR1/2-specific agonist with EC50 = 65 ± 3 nM.
- SMU-C409 features a carbonyl conservation strategy and a quinoline moiety for enhanced stability and solubility (3.4-fold free base, 5.5-fold hydrochloride).
- Mechanistic studies confirmed TLR1/2 activation, MyD88 recruitment, NF-κB phosphorylation, and TNF-α/IL-1β secretion, alongside robust in vitro immune cell activation and antitumor effects.
Conclusions:
- SMU-C409 overcomes key limitations of previous TLR2 agonists, demonstrating high potency, improved stability, and solubility.
- SMU-C409 exhibits significant potential as a candidate for advancing cancer immunotherapy through immune modulation.
